Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors

Srinivas Nagaraj, Vladimir Pisarev, Leo Kinarsky, Simon Sherman, Carlos Muro-Cacho, Dario C. Altieri, Dmitry I. Gabrilovich

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Survivin is a good candidate for cancer immunotherapy since it is overexpressed in most common human cancers, poorly expressed in most normal adult tissues and is essential for cancer cell survival. Previously, we and others have demonstrated that survivin-specific immune responses can be generated in mice and cancer patients. These responses resulted in a substantial antitumor effect. However, the fact that survivin is expressed in normal hematopoietic progenitor cells and endothelial cells may potentially limit the use of vaccination against survivin in the clinic due to possible toxicity. In this study, we have evaluated this risk by using dendritic cells (DC) transduced with an adenovirus encoding mutant human survivin (Ad-surv DCs). Immunization of mice with Ad-surv DCs resulted in generation of CD8 T cells recognizing multiple epitopes from mouse survivin. These responses provided significant antitumor effect against 3 different tumors EL-4 lymphoma, MC-38 carcinoma, and MethA sarcoma. Survivin-specific T-cells did not affect bone marrow hematopoietic progenitor cells and no autoimmune abnormalities were observed. However, as was the case with other tumor vaccines it provided only partial antitumor effect against established tumors. The existing paradigm suggests that generation of immune response against multiple tumor-associated antigens may provide a better antitumor effect. Here, we directly tested this hypothesis by combining vaccines targeting different tumor-associated proteins: survivin and p53. Despite the fact that combination of 2 vaccines generated potent antigen specific T-cell responses against both molecules they did not result in the improvement of antitumor effect in any of the tested experimental tumor models.

Original languageEnglish (US)
Pages (from-to)169-179
Number of pages11
JournalJournal of Immunotherapy
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Dendritic Cells
Vaccines
Neoplasms
Therapeutics
Hematopoietic Stem Cells
T-Lymphocytes
Combined Vaccines
Cancer Vaccines
Neoplasm Antigens
Adenoviridae
Sarcoma
Immunotherapy
Epitopes
Immunization
Lymphoma
Cell Survival
Vaccination
Theoretical Models
Endothelial Cells
Bone Marrow

Keywords

  • Dendritic cells
  • Survivin
  • Tumor vaccine
  • p53

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Nagaraj, S., Pisarev, V., Kinarsky, L., Sherman, S., Muro-Cacho, C., Altieri, D. C., & Gabrilovich, D. I. (2007). Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. Journal of Immunotherapy, 30(2), 169-179. https://doi.org/10.1097/01.cji.0000211329.83890.ba

Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. / Nagaraj, Srinivas; Pisarev, Vladimir; Kinarsky, Leo; Sherman, Simon; Muro-Cacho, Carlos; Altieri, Dario C.; Gabrilovich, Dmitry I.

In: Journal of Immunotherapy, Vol. 30, No. 2, 01.02.2007, p. 169-179.

Research output: Contribution to journalArticle

Nagaraj, S, Pisarev, V, Kinarsky, L, Sherman, S, Muro-Cacho, C, Altieri, DC & Gabrilovich, DI 2007, 'Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors', Journal of Immunotherapy, vol. 30, no. 2, pp. 169-179. https://doi.org/10.1097/01.cji.0000211329.83890.ba
Nagaraj, Srinivas ; Pisarev, Vladimir ; Kinarsky, Leo ; Sherman, Simon ; Muro-Cacho, Carlos ; Altieri, Dario C. ; Gabrilovich, Dmitry I. / Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. In: Journal of Immunotherapy. 2007 ; Vol. 30, No. 2. pp. 169-179.
@article{46fcdb0f20174bfe99496d26296e8ff2,
title = "Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors",
abstract = "Survivin is a good candidate for cancer immunotherapy since it is overexpressed in most common human cancers, poorly expressed in most normal adult tissues and is essential for cancer cell survival. Previously, we and others have demonstrated that survivin-specific immune responses can be generated in mice and cancer patients. These responses resulted in a substantial antitumor effect. However, the fact that survivin is expressed in normal hematopoietic progenitor cells and endothelial cells may potentially limit the use of vaccination against survivin in the clinic due to possible toxicity. In this study, we have evaluated this risk by using dendritic cells (DC) transduced with an adenovirus encoding mutant human survivin (Ad-surv DCs). Immunization of mice with Ad-surv DCs resulted in generation of CD8 T cells recognizing multiple epitopes from mouse survivin. These responses provided significant antitumor effect against 3 different tumors EL-4 lymphoma, MC-38 carcinoma, and MethA sarcoma. Survivin-specific T-cells did not affect bone marrow hematopoietic progenitor cells and no autoimmune abnormalities were observed. However, as was the case with other tumor vaccines it provided only partial antitumor effect against established tumors. The existing paradigm suggests that generation of immune response against multiple tumor-associated antigens may provide a better antitumor effect. Here, we directly tested this hypothesis by combining vaccines targeting different tumor-associated proteins: survivin and p53. Despite the fact that combination of 2 vaccines generated potent antigen specific T-cell responses against both molecules they did not result in the improvement of antitumor effect in any of the tested experimental tumor models.",
keywords = "Dendritic cells, Survivin, Tumor vaccine, p53",
author = "Srinivas Nagaraj and Vladimir Pisarev and Leo Kinarsky and Simon Sherman and Carlos Muro-Cacho and Altieri, {Dario C.} and Gabrilovich, {Dmitry I.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1097/01.cji.0000211329.83890.ba",
language = "English (US)",
volume = "30",
pages = "169--179",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors

AU - Nagaraj, Srinivas

AU - Pisarev, Vladimir

AU - Kinarsky, Leo

AU - Sherman, Simon

AU - Muro-Cacho, Carlos

AU - Altieri, Dario C.

AU - Gabrilovich, Dmitry I.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Survivin is a good candidate for cancer immunotherapy since it is overexpressed in most common human cancers, poorly expressed in most normal adult tissues and is essential for cancer cell survival. Previously, we and others have demonstrated that survivin-specific immune responses can be generated in mice and cancer patients. These responses resulted in a substantial antitumor effect. However, the fact that survivin is expressed in normal hematopoietic progenitor cells and endothelial cells may potentially limit the use of vaccination against survivin in the clinic due to possible toxicity. In this study, we have evaluated this risk by using dendritic cells (DC) transduced with an adenovirus encoding mutant human survivin (Ad-surv DCs). Immunization of mice with Ad-surv DCs resulted in generation of CD8 T cells recognizing multiple epitopes from mouse survivin. These responses provided significant antitumor effect against 3 different tumors EL-4 lymphoma, MC-38 carcinoma, and MethA sarcoma. Survivin-specific T-cells did not affect bone marrow hematopoietic progenitor cells and no autoimmune abnormalities were observed. However, as was the case with other tumor vaccines it provided only partial antitumor effect against established tumors. The existing paradigm suggests that generation of immune response against multiple tumor-associated antigens may provide a better antitumor effect. Here, we directly tested this hypothesis by combining vaccines targeting different tumor-associated proteins: survivin and p53. Despite the fact that combination of 2 vaccines generated potent antigen specific T-cell responses against both molecules they did not result in the improvement of antitumor effect in any of the tested experimental tumor models.

AB - Survivin is a good candidate for cancer immunotherapy since it is overexpressed in most common human cancers, poorly expressed in most normal adult tissues and is essential for cancer cell survival. Previously, we and others have demonstrated that survivin-specific immune responses can be generated in mice and cancer patients. These responses resulted in a substantial antitumor effect. However, the fact that survivin is expressed in normal hematopoietic progenitor cells and endothelial cells may potentially limit the use of vaccination against survivin in the clinic due to possible toxicity. In this study, we have evaluated this risk by using dendritic cells (DC) transduced with an adenovirus encoding mutant human survivin (Ad-surv DCs). Immunization of mice with Ad-surv DCs resulted in generation of CD8 T cells recognizing multiple epitopes from mouse survivin. These responses provided significant antitumor effect against 3 different tumors EL-4 lymphoma, MC-38 carcinoma, and MethA sarcoma. Survivin-specific T-cells did not affect bone marrow hematopoietic progenitor cells and no autoimmune abnormalities were observed. However, as was the case with other tumor vaccines it provided only partial antitumor effect against established tumors. The existing paradigm suggests that generation of immune response against multiple tumor-associated antigens may provide a better antitumor effect. Here, we directly tested this hypothesis by combining vaccines targeting different tumor-associated proteins: survivin and p53. Despite the fact that combination of 2 vaccines generated potent antigen specific T-cell responses against both molecules they did not result in the improvement of antitumor effect in any of the tested experimental tumor models.

KW - Dendritic cells

KW - Survivin

KW - Tumor vaccine

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=34247580137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247580137&partnerID=8YFLogxK

U2 - 10.1097/01.cji.0000211329.83890.ba

DO - 10.1097/01.cji.0000211329.83890.ba

M3 - Article

VL - 30

SP - 169

EP - 179

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 2

ER -